ReviewInfectious diseases & immunity2025
Co-infection with hepatitis B and human immunodeficiency virus: epidemiology, pathogenesis, and treatment.
Review in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- HIV dominates T-cell immune responses in HIV-HBV co-infection and is associated with increased HIV reservoir transcription.Scientific reports · 2026Article
- High prevalence of co-infections with latent tuberculosis, syphilis and hepatitis B and C among people with HIV in Ghana: a call for integrating screening into routine care.AIDS research and therapy · 2025Article
- Immunosenescence and its related comorbidities in older people living with HIV.Infectious diseases & immunity · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Co-infection with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) is common as the modes of disease transmission are similar. HIV affects the development of chronic HBV infection, leading to higher HBV DNA levels, cirrhosis, and end-stage liver duisease, and potentially leading to hepatocellular carcinoma. One of the leading causes of mortality and morbidity in HIV-infected individualsis liver disease, despite the administration of antiretroviral therapy for HIV and HBV. Thus, the screening and follow-up of co-infected patients are vital formonitoring of liver disease progression. This study reviews the natural history and pathogenesis of liver disease in the context of HBV/HIV co-infection, current treatments for HBV in patients with HIV, and treatment outcomes in coinfected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.